Overview

Multiple Dose Study To Investigate The Effects Of Fesoterodine And Solifenacin On Gastrointestinal Transit

Status:
Terminated
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
To assess the effect of fesoterodine 8 mg as compared to solifenacin 10 mg on colonic transit.
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer
Treatments:
Fesoterodine
Solifenacin Succinate